Cyclovirobuxine D: Pharmacological and Bioanalytical Perspectives and Therapeutic Insights

Cyclovirobuxine D (CVB-D) is a steroidal alkaloid extracted from Buxus microphylla, widely used in traditional Chinese medicine for cardiovascular diseases. It has demonstrated significant pharmacological activities, including anti-arrhythmic, cardioprotective, neuroprotective, antiinflammatory, and anti-cancer effects. CVB-D modulates key signaling pathways, such as PI3K/Akt, NF-κB, MAPK, and calcium channel regulation, contributing to its therapeutic potential. Studies indicate that CVB-D induces apoptosis, inhibits cell proliferation, and suppresses tumor metastasis, particularly in lung, gastric, colorectal, and hepatocellular cancers. Additionally, its neuroprotective properties suggest potential applications in neurodegenerative disorders like Alzheimer's and Parkinson's diseases. Beyond its benefits, CVB-D poses challenges related to toxicity, bioavailability, and long-term safety. Reported side effects include hepatotoxicity, nephrotoxicity, and cardiovascular risks, necessitating further clinical investigations. Despite its promising pharmacological profile, preclinical and clinical trials are essential to determine its optimal dosage and therapeutic window. This review provides a comprehensive analysis of CVB-D, including its mechanisms of action, pharmacokinetics, therapeutic potential, and limitations. A deeper understanding of its molecular interactions and safety profile will help guide future drug development and clinical applications.